A dual-engine platform

Stopping resistant infections before they take hold.

Hospital-acquired infections extend patient stays, drive up healthcare costs, and accelerate the spread of antimicrobial resistance. Viropin develops a suite of infection-control products designed for the settings where the risk is highest: surgical units, intensive care, aged care, and high-throughput hospital environments.

Our product line includes:

• MRSA nasal decolonisation: targeting one of the most persistent and costly sources of hospital infection.

• Topical decolonisation therapies: protecting patients identified as carriers before admission, surgery, or transfer.

• Pre-surgical scrubs: reducing surgical site infection risk at the point of greatest vulnerability.

• Hospital antiseptics and environmental sanitation: supporting infection-control protocols across the patient journey.

These are practical, deployable products. They use familiar regulatory pathways, address pain points hospital procurement teams already budget for, and reach market years ahead of any therapeutic.

Making existing antibiotics work again.

Many antibiotics fail not because they are ineffective, but because bacteria have evolved mechanisms to block or evade them. Rather than chase the costly and uncertain pursuit of entirely new antibiotic classes, Viropin's therapeutic platform disrupts these resistance mechanisms, restoring the potency of antibiotics already approved, manufactured, and familiar to clinicians worldwide.

This approach is faster to clinic, lower risk to develop, and immediately useful at scale. It extends the useful life of treatments hospitals already rely on, and gives healthcare systems a practical tool against the most dangerous resistant infections.

Our lead therapeutic programme is on track for IND submission and Phase II clinical trials in 2028, with a global Phase III programme planned for 2029–2031.

Most early-stage biotechs ask investors to wait a decade for a single binary outcome. Viropin is built differently.

Our infection-control products generate revenue, build commercial infrastructure, and establish hospital relationships within the next 18–24 months. That commercial base supports and de-risks the longer therapeutic programme behind it.

Investors get near-term traction and long-term upside from the same platform.